Zentek (CVE:ZEN) Stock Price Up 16.9% - Time to Buy?

Key Points

• Shares jumped 16.9% to C$0.69 on Friday, trading as high as C$0.70 with volume up about 62% to 103,172 shares versus the prior close of C$0.59.
• The company has a market cap of C$74.21 million and a negative P/E (-8.63); its stock remains below the 50‑day (C$0.76) and 200‑day (C$0.95) moving averages, while liquidity and leverage metrics show a high quick ratio (7.59) but elevated debt‑to‑equity (15.41).
• Zentek is a graphene and nanomaterials developer offering products such as ZenGUARD antimicrobial coatings, surgical masks, HVAC filters, PPE, rapid diagnostics and pharmaceutical compounds, and it owns the Albany graphite project in Northern Ontario.

Zentek Ltd. (CVE:ZEN - ) shares rose 16.9% on Friday . The company traded as high as C$0.70 and last traded at C$0.69. Approximately 103,172 shares changed hands during trading, an increase of 62% from the average daily volume of 63,595 shares. The stock had previously closed at C$0.59.

Zentek Trading Up 16.9%

The firm has a market capitalization of C$74.21 million, a price-to-earnings ratio of -8.63 and a beta of 0.36. The business's 50-day simple moving average is C$0.76 and its two-hundred day simple moving average is C$0.95. The company has a quick ratio of 7.59, a current ratio of 1.00 and a debt-to-equity ratio of 15.41.

Zentek Company Profile

Zentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compounds. It is also developing graphene oxide synthesis and graphene synthesis. In addition, the company owns 100% interest in the Albany graphite project located in Northern Ontario, Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.